MAPK is involved in ET-1-induced contraction in rabbit basilar arteries, acting downstream of PTK, Src, and Janus tyrosine kinase pathways, suggesting potential therapeutic targets for cerebral vasospasm.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use in cerebral vasospasm; leaves open MAPK inhibition as a hypothesis-generating target.
Zubkov et al. (2000) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: